Friday 16 October 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.99
0.00
0.00%
Follow LRMR
Larimar Therapeutics, Inc. (LRMR) P/E ratio
Larimar Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PYXS Pyxis Oncology, Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| LRMR Larimar Therapeutics, Inc. | n/m |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)